ATE77943T1 - Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung. - Google Patents

Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.

Info

Publication number
ATE77943T1
ATE77943T1 AT87304188T AT87304188T ATE77943T1 AT E77943 T1 ATE77943 T1 AT E77943T1 AT 87304188 T AT87304188 T AT 87304188T AT 87304188 T AT87304188 T AT 87304188T AT E77943 T1 ATE77943 T1 AT E77943T1
Authority
AT
Austria
Prior art keywords
controlled release
pharmaceutical composition
release pharmaceutical
matrix
contain
Prior art date
Application number
AT87304188T
Other languages
English (en)
Inventor
Gordon Anthony Elger
Stewart Thomas Leslie
Sandra Therese Antoi Malkowska
Ronald Brown Miller
Philip John Neale
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE77943T1 publication Critical patent/ATE77943T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87304188T 1986-06-05 1987-05-12 Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung. ATE77943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868613689A GB8613689D0 (en) 1986-06-05 1986-06-05 Pharmaceutical composition
EP87304188A EP0248548B1 (de) 1986-06-05 1987-05-12 Pharmazeutische Zusammensetzung mit kontrollierter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
ATE77943T1 true ATE77943T1 (de) 1992-07-15

Family

ID=10598992

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87304188T ATE77943T1 (de) 1986-06-05 1987-05-12 Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.

Country Status (15)

Country Link
US (1) US4828836A (de)
EP (1) EP0248548B1 (de)
JP (1) JPH0780787B2 (de)
KR (1) KR890004688B1 (de)
AT (1) ATE77943T1 (de)
AU (1) AU602337B2 (de)
CA (1) CA1297017C (de)
DE (1) DE3780222T2 (de)
DK (1) DK289387A (de)
ES (1) ES2042561T3 (de)
FI (1) FI92014C (de)
GB (1) GB8613689D0 (de)
GR (1) GR3005191T3 (de)
IE (1) IE60757B1 (de)
ZA (1) ZA873735B (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
DE3741149A1 (de) * 1987-12-04 1989-06-15 Thomae Gmbh Dr K Zubereitungsformen zur verhinderung von adhaesionen von organen und organteilen
US5364622A (en) * 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
US5079005A (en) * 1988-06-17 1992-01-07 Gupta Kashmiri L Time release protein
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
DE69115974T2 (de) * 1990-04-09 1996-05-23 Produits Refractaires Kalorienarme gepresste Tabletten mit verbessertem Mundgefühl
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5221698A (en) * 1991-06-27 1993-06-22 The Regents Of The University Of Michigan Bioactive composition
US5225201A (en) * 1991-08-23 1993-07-06 Minnesota Mining And Manufacturing Company Salsalate tablet
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
CA2082185C (en) * 1991-11-26 2004-01-20 Alexander R. Pokora Protease catalyzed treatments of lignocellulose materials
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
EP0742008A1 (de) * 1995-05-11 1996-11-13 Euro-Celtique S.A. Pharmazeutische Zubereitungen mit kontrollierter Wirkstoffabgabe
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
IT1276130B1 (it) 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20060068018A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
SE9704401D0 (sv) * 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
WO2001035961A1 (en) 1999-10-29 2001-05-25 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) * 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
EP1408976B3 (de) * 2001-07-20 2010-08-25 Psychogenics Inc. Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
DE20308437U1 (de) 2002-04-05 2003-11-13 Euroceltique S.A., Luxemburg/Luxembourg Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
EP1515674A4 (de) * 2002-05-13 2008-04-09 Endo Pharmaceuticals Inc Gegen missbrauch geschützte feste opioid-dosierform
WO2004041154A2 (en) * 2002-05-13 2004-05-21 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1549296A4 (de) * 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co Metformin-formulierungen mit verzögerter freisetzung
EP2422775A3 (de) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
ES2359375T3 (es) * 2003-11-04 2011-05-20 Supernus Pharmaceuticals, Inc. Formas de dosificación de dosis única diaria de trospio.
WO2005046663A1 (en) 2003-11-04 2005-05-26 Shire Laboratories, Inc. Compositions of quaternary ammonium containing bioavailability enhancers
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
RU2388466C2 (ru) 2004-04-27 2010-05-10 Медисинова, Инк. Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
US7691874B2 (en) * 2004-05-14 2010-04-06 Hyoung-Chun KIM Neuroprotective properties of dextrorotatory morphinans
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
EP2623099A1 (de) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
ES2613673T3 (es) 2008-08-20 2017-05-25 Cargill, Incorporated Nuevo material de polidextrosa
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
WO2013130354A1 (en) 2012-02-29 2013-09-06 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
EP2858640B1 (de) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Zusammensetzung zur Verwendung in einem Verfahren zur Behandlung von Übergewicht und Fettleibigkeit in Patienten mit hohem Herz-Kreislauf-Risiko
WO2013184902A1 (en) 2012-06-07 2013-12-12 Board Of Regents, The University Of Texas System Chemical transformations of (-)-codeine to afford derivatives of codeine and morphine thereof
RU2015105097A (ru) * 2012-08-23 2016-10-10 Кардиолинкс Аг Композиции аминоалкилнитрата с пролонгированным высвобождением
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20150031769A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
CA2930001A1 (en) 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
KR102435793B1 (ko) 2014-06-02 2022-08-25 메디시노바, 인크. 섬유증의 억제 또는 치료 방법
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
KR102462638B1 (ko) 2014-11-26 2022-11-03 메디시노바, 인크. 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP3897728A1 (de) * 2018-12-18 2021-10-27 DDP Specialty Electronic Materials US, Inc. Zusammensetzung mit einer hydroxyalkylmethylcellulose mit verzögerter freisetzung
CA3217719A1 (en) 2021-05-28 2022-12-01 Kazuko Matsuda Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766165A (en) * 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
US4327077A (en) * 1981-05-29 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4548806A (en) * 1982-07-23 1985-10-22 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US4459280A (en) * 1982-07-23 1984-07-10 G. D. Searle & Co. Psyllium hydrophilic mucilloid composition
US4698264A (en) * 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
US4668510A (en) * 1984-08-07 1987-05-26 Euroceltique, S.A. Iodophor composition
US4576818A (en) * 1984-08-07 1986-03-18 Euroceltique, S.A. Iodophor composition

Also Published As

Publication number Publication date
FI92014C (fi) 1994-09-26
KR890004688B1 (ko) 1989-11-25
ZA873735B (en) 1987-11-23
IE871480L (en) 1987-12-05
AU602337B2 (en) 1990-10-11
CA1297017C (en) 1992-03-10
IE60757B1 (en) 1994-08-10
EP0248548B1 (de) 1992-07-08
JPS62292732A (ja) 1987-12-19
KR880000089A (ko) 1988-03-23
EP0248548A2 (de) 1987-12-09
ES2042561T3 (es) 1993-12-16
DE3780222D1 (de) 1992-08-13
FI872481A (fi) 1987-12-06
JPH0780787B2 (ja) 1995-08-30
FI92014B (fi) 1994-06-15
AU7378787A (en) 1987-12-10
GR3005191T3 (de) 1993-05-24
DE3780222T2 (de) 1993-02-25
DK289387A (da) 1987-12-06
EP0248548A3 (en) 1988-03-30
GB8613689D0 (en) 1986-07-09
FI872481A0 (fi) 1987-06-03
DK289387D0 (da) 1987-06-04
US4828836A (en) 1989-05-09

Similar Documents

Publication Publication Date Title
ATE77943T1 (de) Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.
DE68919146D1 (de) Ausgewählte Stämme von Lactobacillus enthaltende pharmazeutische Zusammensetzungen.
ES2186715T3 (es) Uso de un tensioactivo lipofilico en una composicion farmaceutica.
NL300136I2 (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
MX9201298A (es) Nuevos conjugados de proteinas con poli etilen glicol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
FI875272A (fi) Baerarloesningsmedelssystem i tvao fas.
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
ATA154489A (de) Feste pharmazeutische ranitidinpraeparate
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
ITMI922603A1 (it) Composizioni farmaceutiche comprendenti un farmaco, una sostanza polimerica reticolata, un olio ed un agente tensioattivo
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
SE8804628D0 (sv) New compounds
SE8401538L (sv) Forbettrade analgetiska och anti-inflammatoriska kompositioner innefattande koffein och forfaranden for anvendning av dessa
DE69012031D1 (de) Optisch aktive Benzylalkoholverbindung und pharmazeutische Zusammensetzung.
ATE70445T1 (de) Pharmazeutische praeparate.
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
FI920118A0 (fi) Substituerade 2-imidazoliner samt framstaellning och anvaendning av dem.
DE3877365D1 (de) Arzneimittel mit methylcellulose.
ATE142880T1 (de) Penciclovir enthaltende pharmazeutische formulierung
DE69003466D1 (de) Substituierte Thienopyrimidin-Derivate, deren Herstellung, pharmazeutische Zusammensetzungen und medizinische Verwendung.
DE3863830D1 (de) Arzneimittelformulierung.
NL193441B (nl) Farmaceutisch preparaat voor veterinair gebruik.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
DE58905160D1 (de) Pharmazeutische zubereitung.
DE3871159D1 (de) Pharmazeutische und tieraerztliche zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee